Abiopharma

Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

(85% Positive) ENTRADA THERAPEUTICS, INC. (TRDA) Announces Clinical Development Update

Indivior Notification

(90% Positive) CULLINAN THERAPEUTICS, INC. (CGEM) Announces Enrollment Update for dosing Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(90% Positive) Opus Genetics, Inc. (OCUP) Announces Enrollment Update for qualify Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(80% Positive) Invivyd, Inc. (IVVD) Announces Enrollment Update for preparing Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(10% Negative) Standard BioTools Inc. (LAB) Announces Business Combination

(90% Positive) VANDA PHARMACEUTICALS INC. (VNDA) Provides Update on effectiveness for Jet Lag DisorderJanuary 8

(90% Positive) CLIMB BIO, INC. (ELYM) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Canopy Growth Communication - Canopy Growth Announces Strategic Recapitalization Transactions Significantly Strengthening Balance Sheet to Support Growth Strategy

(90% Positive) AMARIN CORP PLC\UK (AMRN) Provides Update on meetings for our operating expenses

(10% Negative) AMYLYX PHARMACEUTICALS, INC. (AMLX) Files Form 8-K